|Traded as||Euronext: SAN, NYSE: SNY, LSE: 0I42, FWB: SNW|
|Founded||20 August 2004 (by acquisition) as Sanofi Aventis
6 May 2011 as Sanofi
|Headquarters||54, rue La Boétie, 8th arrondissement, Paris, France|
|Key people||Chris Viehbacher (CEO), Serge Weinberg (Chairman), Jean-François Dehecq (Original Founder)|
|Products||Prescription and over-the-counter drugs for thrombosis, cardiovascular disease, diabetes, central nervous system disorders, oncology and internal medicine, vaccines (list...)|
|Revenue||€33.38 billion (2011)|
|Operating income||€7.499 billion (2011)|
|Profit||€5.693 billion (2011)|
|Total assets||€100.16 billion (2011)|
|Total equity||€56.38 billion (2011)|
Sanofi S.A. is a French multinational pharmaceutical company headquartered in Paris, France, the world's fourth-largest by prescription sales. Sanofi engages in the research and development, manufacturing and marketing of pharmaceutical products for sale principally in the prescription market, but the firm also develops over-the-counter medication. The company covers 7 major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines (it is the world's largest producer of the latter through its subsidiary Sanofi Pasteur). Sanofi is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The company was formed as Sanofi-Aventis in 2004 by the merger of Aventis and Sanofi-Synthélabo. It changed its name to Sanofi in May 2011. In January 2012, Sanofi announced that they will invest $125 million in Warp Drive Bio to support their cancer research program.
|This section needs additional citations for verification. (April 2009)|
Sanofi was founded 10 September 1973 as subsidiary of Elf Aquitaine, a French oil company, when it took control of the Labaz group, a pharmaceutical company. Its first significant venture into the U.S. market was the acquisition of the prescription pharmaceuticals business of Sterling Winthrop — an affiliate of Eastman Kodak — in 1994. Sanofi was incorporated under the laws of France in 1994 as a société anonyme, a form of limited liability company, for a term of 99 years.
Synthélabo was founded in 1970 through the merger of two French pharmaceutical laboratories, Laboratoires Dausse (founded in 1834) and Laboratoires Robert & Carrière (founded in 1899). In 1973, the French cosmetics group L’Oréal acquired the majority of its share capital.
Aventis was formed in 1999 when French company Rhône-Poulenc S.A. merged with the German corporation Hoechst Marion Roussel, which itself was formed from the 1995 merger of Hoechst AG with Roussel Uclaf and Marion Merrell Dow. The merged company was based in Schiltigheim, near Strasbourg, France.
Sanofi-Synthélabo took control of Aventis in August 2004 and changed its registered name to “Sanofi-Aventis”. On 31 December 2004, Aventis merged with and into Sanofi-Aventis, with Sanofi-Aventis as the surviving company.
Starting in 2009, Sanofi made a series of acquisitions to create or strengthen its regional CHC and generics platforms including:
- The Prague-based branded generics group Zentiva
- Medley, the third largest pharmaceutical company in Brazil and a leading generics company in that country
- Chattem, Inc., a leading U.S. consumer healthcare company.
- BMP Sunstone Corporation
- Genzyme Corporation, a leading biotechnology group headquartered in Cambridge, Massachusetts and specialized in the treatment of rare diseases, renal diseases, endocrinology, oncology and biosurgery.
As of the May 2011 General Meeting of Shareholders, the Group changed its name to “Sanofi”
Merger and beyond
Sanofi-Aventis was formed in 2004 when Sanofi-Synthélabo acquired Aventis. In early 2004, Sanofi-Synthélabo made a hostile takeover bid worth €47.8 billion for Aventis. Initially, Aventis rejected the bid because it felt that the bid offered inferior value based on the company's share value. The three-month takeover battle concluded when Sanofi-Synthélabo launched a friendly bid of €54.5 billion in place of the previously rejected hostile bid. French government intervention also played an active role. The French government, desiring what they called a "local solution", put heavy pressure on Sanofi-Synthélabo to raise its bid for Aventis after it became known that Novartis, a Swiss pharmaceutical company, was in the running.
October 2010: Sanofi-Aventis SA laid off 1,700 US employees due to restructuring triggered by growing generic competition and other factors. The cuts were completed throughout 2011 according to transition needs. The layoffs amount to about 25 percent of the company's US pharmaceutical operation. The company denies the action was related with acquisition plan of buying US biotech firm Genzyme Corp.
The company dropped the -Aventis suffix of its name on 6 May 2011 after receiving approval at its AGM. The reason given by the company for the change was to make its name easier to pronounce in countries such as China.
Contaminated products and legal issues
In 1984 and 1985, the Marion institute which is now owned by Sanofi issued factors contaminated with HIV for hemophiliacs from West Germany, Italy, Argentina, Saudi Arabia, and Iran. The latter country's Blood Transfusion Organization has so far been unsuccessful in making the company make up for the damage, despite compensations it has paid to the patients.
- Glimepiride (Amaryl) for type 2 diabetes mellitus
- Human Insulin (Insuman) for type 1 and type 2 diabetes mellitus
- Alfuzosin (Xatral) for benign prostatic hyperplasia
- Cabazitaxel (Jevtana) for prostate cancer
- Mozobil:for non-hodgekens lemphoma and multible myloma
- Clomifene (Clomid) for Female infertility
- Clopidogrel (Plavix, Iscover) for atherothrombosis
- Codeine (Solpadol) for Chronic pain
- Docetaxel (Taxotere) for breast, lung and prostate cancer
- Enoxaparin (Lovenox, Clexane) for thrombosis (its biggest seller in 2008)
- Fexofenadine (Allegra, Telfast) and Triamcinolone (Nasacort) for allergic rhinitis
- Insulin glulisine (Apidra) and Insulin glargine (Lantus) for diabetes
- Irbesartan (Aprovel, Avapro, Delix, Karvea, Triatec, Tritace) for hypertension
- Ketoprofen (Bi-profined) for pain
- Menactra for meningitis
- Oxaliplatin (Eloxatin) for colorectal cancer
- Risedronic acid (Actonel) for osteoporosis and Paget’s disease
- Renagel and Renvela (Sevelamer Hydrochloride) for end stage renal disease
- Valproic acid (Depakine) and Valproate semisodium (Depakote) for epilepsy
- Zolpidem (Ambien, Ambien CR, Myslee, Stilnoct, Stilnox, Zolfresh, Zolt) for insomnia
- vaccines:Bacterial diseases:Cholera Diphtheria -Haemophilus influenzae type b-infections Meningococcal- Infections Pertussis Pneumococcal- Infections Tetanus -Tuberculosis Typhoid Fever
- Viral diseases:Hepatitis A Hepatitis B Influenza Japanese Encephalitis Measles Mumps Poliomyelitis Rabies Rubella VaricellaYellow Fever And Smallpox, eradicated in 1980 (vaccine produced as a measure in response to the threat of bioterrorism)
- antibiotics:claforan (cefotaxime)-wintriaxone (cefatriaxone)
- amoklawin :amoxacilline&clavunilic acid
The company also produces a broad range of over-the-counter products, among them Allegra, IcyHot for muscle pain, Gold Bond for skin irritation, and Selsun Blue dandruff shampoo (these brands were acquired in 2010 when Sanofi-Aventis purchased Chattem).
- Serge Weinberg, Chairman
- Chris Viehbacher, CEO
- Jean-François Dehecq was the General Manager of Sanofi from its creation in 1973 until 2007.
As of 31 January 2011:
- Breakdown of share ownership: 5.16% by Total, 9.02% by L'Oréal, 0.46% treasury shares and 1.43% employees. The remaining 83.93% are publicly traded.
- Voting rights distribution: 8.89% to Total, 15.61% to L'Oréal, 2.33% to employees, and 73.17% to the public.
In January 2012, Sanofi moved its head office location to 54, rue La Boétie in the 8th arrondissement of Paris. This former mansion designed by architect René-Patouillard had previously been the head office of Alcatel-Lucent.
Sanofi's previous head office was located in the 13th arrondissement of Paris, 174 Avenue de France. The architecture of the head office is of the predominate style of the area surrounding the François Mitterrand Library. After Sanofi and Aventis merged, the employees at the former Aventis head office in Schiltigheim, Alsace moved to Paris.
In addition to internal research and development activities Sanofi is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox. The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.
The Aventis Foundation, a German charitable trust, was established in 1996 as the Hoechst Foundation with an endowment of €50 million. In 2000, the foundation was renamed the Aventis Foundation. Its aim is to promote music, theater, art, literature, higher education and healthcare research.
- "Annual Report 2010". Sanofi-Aventis. Retrieved 13 April 2011.
- IMS Health 2008
- Keller, Greg (10 September 2008). "Sanofi names Viehbacher as new CEO". USA Today. Associated Press. Retrieved 2009-04-19.
- "Sanofi-Aventis to sign deal to build flu vaccine plant in China - source". AFX News (Forbes). 23 November 2007. Retrieved 2009-04-19.
- "The Pharmaceutical Industry in Figures - 2008 Edition". European Federation of Pharmaceutical Industries and Associations (EFPIA). p. 49. Retrieved 2008-08-25.
- Sanofi-Aventis To Lay Off 1,700 US Employees http://www.cbsnews.com/stories/2010/10/08/ap/health/main6939445.shtml
- Mennella, Noelle (6 May 2011). "Sanofi changes name, pace of acquisitions to slow". Reuters. Retrieved 7 May 2011.
- Iran not experienced enough to charge French company for contaminated blood. Yjc.ir (2013-09-17). Retrieved on 2013-12-23.
- "Annual Review 2008". Sanofi-Aventis. Retrieved 2009-04-19.
- Chris Viehbacher wird Nachfolger von Sanofi-Aventis-Chef Le Fur 10.09.2008
- "Sanofi-Aventis : regroupement à Paris." Le Journal du Net. Retrieved on 28 September 2010.
- Mattes, William B. (2008). "Public Consortium Efforts in Toxicogenomics". In Mendrick, Donna L.; Mattes, William B. Essential Concepts in Toxicogenomics. Methods in Molecular Biology 460. pp. 221–238. doi:10.1007/978-1-60327-048-9_11. ISBN 978-1-58829-638-2. PMID 18449490.
- "InnoMed PredTox Member Organizations". Retrieved 2008-08-25.
- Innovative Medicines Initiative. "IMI Call Topics 2008". IMI-GB-018v2-24042008-CallTopics.pdf. European Commission. Retrieved 2008-08-25.[dead link]
- Sanofi-aventis, Charite University Sign Cooperation Agreement News article from InfoGrok.
- "Sanofi Earns Slump in Q3 as Competition Heats Up". The New York Times. 25 October 2012.
- "Sanofi pasteur Awarded $97 Million HHS Contract to Accelerate Cell-Culture Pandemic Influenza Vaccine Development". 4 January 2005. Retrieved 12 June 2013.
- Home. Aventis Foundation (2013-11-27). Retrieved on 2013-12-23.